Martingale Asset Management’s Sutro Biopharma STRO Stock Holding History

Martingale Asset Management’s Portfolio STRO Stock Details STRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,062	Closed	-$457K	–	870
2021 Q4	$457K	Buy	+3,062	New	+$549K	0.01%	663
2020 Q4	–	Sell	-5,161	Closed	-$519K	–	1036
2020 Q3	$519K	Sell	5,161 -3,300	-39%	-$312K	0.01%	804
2020 Q2	$657K	Buy	+8,461	New	+$812K	0.01%	824

Other funds holding STRO

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Martingale Asset Management's STRO Position: Q1 2022 in Review

Martingale Asset Management sold out of Sutro Biopharma (STRO) in Q1 2022, closing a stake of 3,062 shares — an estimated $457K sold.

Martingale Asset Management first reported a position in STRO in Q2 2020 and held it in 3 quarters. The position peaked at $657K in Q2 2020. 114 funds tracked by Wall St. Rank hold STRO as of Q1 2022.

Martingale Asset Management reported no remaining Sutro Biopharma position as of Q1 2022 after selling out during the quarter.
Martingale Asset Management sold 3,062 Sutro Biopharma shares in Q1 2022, an estimated $457K.
Martingale Asset Management first reported a position in Sutro Biopharma in Q2 2020 and held it in 3 quarters.
Martingale Asset Management's Sutro Biopharma position peaked at $657K in Q2 2020.
114 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2022.

Based on Martingale Asset Management's 13F filing for Q1 2022, filed 12 May 2022.